Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial

摘要: To assess the response rate and tolerance of irinotecan as first-line therapy, 40 patients with metastatic gastric cancer received 350 mg m(-2) every 3 weeks administered a 30 min infusion. Among 35 evaluable for response, two complete five partial responses were recorded (response rate: 20.0% (95% CI:8.4-36.9%)). In total, 16 achieved stable disease 12 progressive disease. all, 66 percent benefited from tumour growth control. The median time to progression was 3.0 months CI: 2.3-4.4%). overall survival 7.1 5.2-9.0%). probability being alive at 6 9 61.0 32.4%, respectively. number cycles per patient (range 1-14), relative dose intensity 0.98. most common grade 3-4 toxicities by diarrhoea 20%, asthenia 10%, nausea 7.5%, vomiting 5.0%, abdominal pain 5%, neutropenia 38.5%, leucopenia 28.2%, anaemia 12.8% thrombocytopenia 5.1%. Febrile occurred in 12.5% patients. These findings indicate that is active well tolerated adenocarcinoma warrants further evaluation this clinical setting.